Havax Forte is indicated for the treatment of acute uncomplicated Plasmodium falciparum malaria in adults, children, and infants weighing 5 kg and above.
Two tablets twice a day (morning and evening) for three days with a high-fat meal or fatty drink. A total of 12 tablets over three days. Repeat dose if vomiting occurs within 1 hour.
Hypersensitivity to components, severe malaria, drugs metabolized by CYP2D6, family history of sudden death or prolonged QTc interval, drugs that prolong the QTc interval, history of cardiac arrhythmias, bradycardia, or congestive heart failure, electrolyte imbalances, and strong CYP3A4 inducers.
Caution with hormonal contraceptives and drugs that interact with CYP3A4. Also, caution in patients with severe hepatic impairment.
Drugs that prolong the QTc interval, drugs metabolized by CYP2D6, strong CYP3A4 inducers, hormonal contraceptives, and drugs that inhibit, moderately induce, or compete for CYP3A4.
Headache, dizziness, decreased appetite, palpitations, vomiting, abdominal pain, nausea, arthralgia, and fatigue.
80 mg of artemether and 480 mg of lumefantrine.
Artemether and lumefantrine interfere with heme conversion to hemozoin within the malarial parasite. They also inhibit nucleic acid and protein synthesis.
Symptomatic and supportive therapy, including ECG and blood potassium monitoring.
Not recommended, especially during the first trimester of pregnancy and during lactation.
Artemether is rapidly metabolized by CYP3A4/5 to dihydroartemisinin. Both have a short half-life (around 2 hours). Lumefantrine is eliminated more slowly, with a half-life of 2 to 6 days.